

Validation and Clinical Implementation of Parkinson's Disease and Breast Cancer Biomarkers for Diagnosis and Treatment Response Monitoring

<https://www.neurodegenerationresearch.eu/survey/validation-and-clinical-implementation-of-parkinsons-disease-and-breast-cancer-biomarkers-for-diagnosis-and-treatment-response-monitoring/>

Principal Investigators

Eleanor Coffey

Institution

Åbo Akademi

Contact information of lead PI

Country

Finland

Title of project or programme

Validation and Clinical Implementation of Parkinson's Disease and Breast Cancer Biomarkers for Diagnosis and Treatment Response Monitoring

Source of funding information

Tekes

Total sum awarded (Euro)

€ 1,270,000

Start date of award

01/01/2016

Total duration of award in years

4.0

The project/programme is most relevant to:

Parkinson's disease & PD-related disorders

Keywords

Research Abstract

The main aim is to improve diagnostics and disease stratification and treatment response monitoring in two main areas: Parkinson's disease and breast cancer. The focus is on early detection and characterisation of disease in a format that can be implemented in a standard clinical chemistry setting. The development of an early detection method for Parkinsonism is a pre-requisite for prevention of further degeneration. This will be of tremendous utility to both the doctors treating the patients and to the pharmaceutical industry to allow monitoring of treatment. The benefit to society on an economic level would be enormous and one could not put a price on the early treatment of a patient allowing a much longer period of disease free life. The breast cancer diagnostics developed would allow patients a much better quality of life, allowing a rapid detection of non-response to chemotherapy allowing a change in treatment within weeks of instead of several months. Early detection would also save lives since response is much higher the earlier the stage of cancer. Finally the differential diagnosis of hormone status between the primary tumour and subsequent recurrences could significantly affect treatment choice and outcome.

Lay Summary

Further information available at:

Types:

Investments > €500k

Member States:

Finland

Diseases:

Parkinson's disease & PD-related disorders

Years:

2016

Database Categories:

N/A

Database Tags:

N/A